Equities

QuidelOrtho Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert

QuidelOrtho Corp

Actions
  • Price (EUR)24.40
  • Today's Change0.000 / 0.00%
  • Shares traded40.00
  • 1 Year change-41.06%
  • Beta0.7168
Data delayed at least 15 minutes, as of Feb 10 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.

  • Revenue in USD (TTM)2.71bn
  • Net income in USD-1.18bn
  • Incorporated2021
  • Employees6.60k
  • Location
    QuidelOrtho Corp9975 Summers Ridge RoadSAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 552-1100
  • Fax+1 (858) 453-4338
  • Websitehttps://www.quidelortho.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.